Mode
Text Size
Log in / Sign up
N/A N=90

Precision Assessment of Platelet Rich Plasma for Joint Preservation

Osteoarthritis

Enrolled (actual)
90
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Number of Participants With Successful Knee Pain Improvement Over 6 Months Following PRP Injections — 25 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Successful Knee Pain Improvement Over 6 Months Following PRP Injections
25
PRIMARY
Number of Participants With Successful Knee Function Improvement Over 6 Months Following PRP Injections
12

Summary

Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop knee OA at higher rates and younger ages than the population in general. For those with symptomatic early knee OA, who are years to decades away from meeting clinical indications for knee replacement surgery, knee injections have been a key treatment option. In recent years, platelet rich plasma (PRP) injections have gained increasing attention for improving pain and function in patients with knee OA. Basic science studies also suggest that PRP may also potentially stimulate repair responses to articular cartilage. However, the mechanisms of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used, the PRP composition differs between patients. It is also unknown whether these differences in PRP composition affect clinical outcomes. This study will address these gaps and provide critical new and objective information on PRP treatment effects in Veterans and additional women with early knee OA important to improving clinical use of this new treatment.

Eligibility Criteria

Inclusion Criteria

  • symptomatic early knee OA
  • full weight-bearing status
  • have elected to receive PRP treatment
  • Male veterans
  • Female veterans

Exclusion Criteria

  • inflammatory arthritis, gout or recurrent pseudogout
  • symptomatic OA of other lower extremity joints
  • BMI >35 kg/m2
  • use of walking, orthopedic, or prosthetic assistive device
  • severe systemic disease defined as American Society of Anesthesiologists (ASA) 3 or above56
  • inability to have MRI
  • pregnant or intending to become pregnant during the study
  • predominantly patellofemoral disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03460236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search